- Adherence is a critical issue to address in patients who are prescribed metformin.
- Sulfonylureas are still recommended as the standard initial option for addition to metformin.
- Treatment algorithms reflect the complexity of treatment decisions but offer consistent guidance on a stepped/progressive approach to blood glucose control.
Empagliflozin indications extended
Empagliflozin is now TGA-approved for reducing cardiovascular deaths in patients with type 2 diabetes with established cardiovascular disease.
What is the evidence, and what does this mean in clinical practice?
MedicineWise News: Type 2 diabetes – when metformin is not enough
Sulfonylureas are the usual add-on treatment when metformin is no longer sufficient, but are they the best? Review the evidence on efficacy, safety and outcomes for second-line type 2 diabetes treatments.
NPS RADAR: Pharmacological therapies in Australia for type 2 diabetes
Metabolic syndrome and diabetes: how much blame does sugar deserve?
An increasing number of journal articles and media stories are highlighting the potential role of dietary sugar, and particularly added fructose, as a major contributor to ill health, from cardiovascular disease to type 2 diabetes to metabolic syndrome.
Australian Prescriber: Encouraging adherence to long‑term medication
Aust Prescr 2017;40:147-501
Patients should be asked about adherence at every consultation.
Learn more about:
- using a collaborative communication style
- using the patient’s own expressions and responding to their cues
- how to normalise non-adherence
- using open questions and more specific probes.
Episode 6 – Encouraging adherence to long-term medication, with Prof Tim Usherwood
Dr Janine Rowse interviews Professor Tim Usherwood about the different types of medication non-adherence and his practical recommendations for better identification in the primary care setting.
Consolidate your knowledge about type 2 diabetes, brush up on current guidelines and practices and earn CPD points through our learning activities.